Your browser is no longer supported. Please, upgrade your browser.
Settings
GKOS Glaukos Corporation daily Stock Chart
GKOS [NYSE]
Glaukos Corporation
Index- P/E- EPS (ttm)-1.11 Insider Own1.30% Shs Outstand43.77M Perf Week-1.76%
Market Cap1.68B Forward P/E- EPS next Y-0.86 Insider Trans-26.83% Shs Float42.86M Perf Month-3.53%
Income-37.30M PEG- EPS next Q-0.79 Inst Own- Short Float13.92% Perf Quarter12.01%
Sales238.30M P/S7.07 EPS this Y202.20% Inst Trans2.18% Short Ratio8.30 Perf Half Y-33.66%
Book/sh14.65 P/B2.59 EPS next Y54.70% ROA-6.80% Target Price43.00 Perf Year-50.75%
Cash/sh3.69 P/C10.29 EPS next 5Y8.00% ROE-8.80% 52W Range23.31 - 84.65 Perf YTD-30.31%
Dividend- P/FCF- EPS past 5Y23.90% ROI2.10% 52W High-55.16% Beta1.76
Dividend %- Quick Ratio4.00 Sales past 5Y39.10% Gross Margin73.10% 52W Low62.85% ATR1.97
Employees600 Current Ratio4.50 Sales Q/Q2.40% Oper. Margin-42.40% RSI (14)46.39 Volatility4.65% 4.65%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin-15.60% Rel Volume0.48 Prev Close37.43
ShortableYes LT Debt/Eq0.09 EarningsMay 07 AMC Payout- Avg Volume718.73K Price37.96
Recom2.80 SMA20-2.21% SMA50-2.48% SMA200-23.90% Volume341,411 Change1.42%
Jun-15-20Initiated Jefferies Hold $44
Mar-05-20Initiated Citigroup Sell $40
Feb-28-20Downgrade JP Morgan Overweight → Neutral $55
Jan-06-20Upgrade Berenberg Hold → Buy $60 → $65
Dec-12-19Downgrade Wells Fargo Outperform → Underperform
Sep-30-19Downgrade BofA/Merrill Buy → Underperform
Mar-08-19Initiated BTIG Research Neutral
Aug-30-18Initiated Berenberg Hold $57
Aug-29-18Upgrade JP Morgan Neutral → Overweight
Aug-03-18Reiterated Stifel Hold $32 → $35
Jun-21-18Downgrade JP Morgan Overweight → Neutral
Apr-13-18Downgrade Stifel Buy → Hold $39 → $32
Mar-01-18Reiterated Cantor Fitzgerald Buy $48 → $43
Mar-02-17Reiterated Cantor Fitzgerald Overweight $45 → $54
Jan-06-17Upgrade Stifel Hold → Buy $42 → $45
Oct-27-16Initiated Wells Fargo Outperform
Aug-02-16Reiterated Cantor Fitzgerald Buy $35 → $41
Jun-03-16Initiated Cantor Fitzgerald Buy $35
Apr-08-16Initiated Stifel Hold
Feb-09-16Initiated Piper Jaffray Overweight $19
Jun-28-20 05:43PM  
Jun-18-20 07:43AM  
Jun-09-20 06:30PM  
Jun-08-20 10:42PM  
07:06AM  
Jun-06-20 11:31AM  
Jun-03-20 11:19PM  
Jun-02-20 04:30PM  
May-15-20 08:00AM  
May-09-20 11:01AM  
May-08-20 08:50AM  
May-07-20 08:40PM  
04:10PM  
Apr-21-20 08:30AM  
Apr-09-20 09:00AM  
Apr-08-20 08:48PM  
Mar-28-20 11:30AM  
Mar-24-20 09:00AM  
02:19AM  
Mar-10-20 09:19AM  
Mar-09-20 07:02PM  
Mar-02-20 08:37AM  
Feb-27-20 04:15PM  
06:35AM  
Feb-20-20 12:31PM  
Feb-07-20 10:52AM  
07:42AM  
Feb-06-20 04:15PM  
Feb-04-20 07:57AM  
Jan-22-20 07:51AM  
Jan-03-20 07:15AM  
Dec-17-19 07:20AM  
Dec-14-19 09:43PM  
Dec-13-19 04:50PM  
Dec-06-19 11:31AM  
Nov-21-19 08:43AM  
Nov-20-19 04:15PM  
Nov-11-19 12:07PM  
Nov-08-19 09:08AM  
Nov-06-19 07:45PM  
04:10PM  
Oct-30-19 04:15PM  
10:34AM  
Oct-29-19 01:57PM  
Oct-22-19 04:15PM  
Oct-10-19 07:00AM  
Oct-09-19 04:15PM  
Oct-08-19 04:15PM  
Sep-26-19 09:52AM  
Sep-19-19 12:51PM  
Sep-13-19 07:00AM  
Sep-08-19 02:00PM  
Sep-06-19 09:31AM  
Aug-27-19 04:15PM  
Aug-14-19 08:15AM  
Aug-13-19 12:32PM  
Aug-12-19 07:40AM  
Aug-08-19 02:25PM  
11:32AM  
07:11AM  
06:50AM  
02:24AM  
Aug-07-19 07:25PM  
04:15PM  
04:10PM  
Jul-31-19 04:20PM  
Jul-30-19 10:59AM  
Jul-29-19 08:39AM  
Jul-22-19 07:00AM  
07:00AM  
Jul-04-19 12:44PM  
Jun-27-19 04:15PM  
Jun-23-19 03:40PM  
Jun-20-19 07:25AM  
Jun-19-19 04:15PM  
Jun-07-19 02:01PM  
09:30AM  
Jun-04-19 04:15PM  
May-10-19 01:24AM  
May-09-19 01:26PM  
12:07AM  
May-08-19 07:35PM  
06:27PM  
04:10PM  
02:30AM  
May-01-19 04:15PM  
10:32AM  
Apr-30-19 08:13PM  
07:00AM  
Apr-26-19 03:05AM  
Apr-17-19 04:15PM  
Apr-15-19 07:00AM  
Apr-12-19 01:31PM  
Apr-02-19 10:20AM  
Apr-01-19 07:15AM  
Mar-15-19 07:00AM  
Mar-13-19 04:15PM  
01:06PM  
Mar-12-19 04:15PM  
Mar-07-19 08:16AM  
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery. The company's product pipeline includes iStent Infinite trabecular micro-bypass system, which is used as a standalone procedure in patients with refractory glaucoma; iStent Supra suprachoroidal micro-bypass stent that is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; iStent SA trabecular micro-bypass system, a two-stent product, which uses a different auto-injection inserter designed for use in a standalone procedure; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration. The company markets its products through direct sales force in the United States and other 16 countries, as well as through distribution partners in Europe, the Asia Pacific, Latin America, and internationally. Glaukos Corporation was founded in 1998 and is headquartered in San Clemente, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Burns Thomas WilliamChief Executive OfficerMay 26Option Exercise3.98207,447824,602513,336May 27 08:10 PM
Burns Thomas WilliamChief Executive OfficerMay 26Sale39.23207,4478,137,527305,889May 27 08:10 PM
Burns Thomas WilliamChief Executive OfficerMay 20Option Exercise3.984001,590306,289May 22 07:23 PM
Burns Thomas WilliamChief Executive OfficerMay 20Sale38.0540015,221305,889May 22 07:23 PM
Burns Thomas WilliamChief Executive OfficerFeb 28Option Exercise5.59212,5961,188,419272,499Mar 02 07:24 PM
Gilliam Joseph ECFO, SVP Corporate DevelopmentFeb 12Option Exercise41.693,750156,33851,278Feb 14 04:31 PM
Gilliam Joseph ECFO, SVP Corporate DevelopmentFeb 12Sale68.503,750256,87547,528Feb 14 04:31 PM
Burns Thomas WilliamChief Executive OfficerDec 20Option Exercise3.9810,00039,75058,807Dec 23 07:07 PM
Burns Thomas WilliamChief Executive OfficerDec 09Option Exercise3.703,58313,25748,807Dec 11 07:39 PM
Gilliam Joseph ECFO, SVP Corporate DevelopmentSep 30Option Exercise30.924,631143,19152,159Oct 02 04:02 PM
Gilliam Joseph ECFO, SVP Corporate DevelopmentSep 30Sale59.754,631276,70247,528Oct 02 04:02 PM
Gilliam Joseph ECFO, SVP Corporate DevelopmentSep 12Option Exercise41.692,500104,22550,028Sep 12 07:12 PM
Gilliam Joseph ECFO, SVP Corporate DevelopmentSep 12Sale73.252,500183,12547,528Sep 12 07:12 PM
Gilliam Joseph ECFO, SVP Corporate DevelopmentSep 10Option Exercise41.693,750156,33851,278Sep 12 07:12 PM
Gilliam Joseph ECFO, SVP Corporate DevelopmentSep 10Sale68.503,750256,87547,528Sep 12 07:12 PM
Gilliam Joseph ECFO, SVP Corporate DevelopmentAug 26Option Exercise30.924,631143,19152,159Aug 28 05:53 PM
Gilliam Joseph ECFO, SVP Corporate DevelopmentAug 26Sale59.164,631273,97047,528Aug 28 05:53 PM
Gilliam Joseph ECFO, SVP Corporate DevelopmentJul 22Option Exercise37.4310,346387,21153,778Jul 24 05:28 PM
Gilliam Joseph ECFO, SVP Corporate DevelopmentJul 22Sale75.4110,346780,14147,528Jul 24 05:28 PM